Psychiatric disorders in patients with Behçet's disease

References

• Behçet H. Uber rezidivierende aphthouse durch ein virus verurscahte Geschwuere am Mund, am Auge und an den Genitalien. Dermatol Monatsschr Wochenschr 1937; 105: 1152–7
   Google Scholar
• Schirmer M, Calamia KT, Direskeneli H. Ninth International Conference on Behçet's Disease, Seoul, Korea, May 27–29, 2000. J Rheumatol 2000; 28: 636–9
   Google Scholar
• Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet's disease. Semin Arthritis Rheum 1998; 27: 197–217
   PubMed Web of Science ®Google Scholar
• Hegeb S, Al-Mutawa S. Immunopathogenesis of Behçet's disease. Clin Immunol 2000; 96: 174–86
   PubMed Web of Science ®Google Scholar
• Koptagel-Ilal G, Tunçer Ö, Enbiyaoğlu G, Bayramoğlu Z. A psychosomatic investigation of Behçet's disease. Psychother Psychosom 1983; 40: 263–71
   PubMed Web of Science ®Google Scholar
• Karlidağ R, Ünal S, Evereklioğlu C, Sipahi B, Er H, Yoloğlu S. Stressful life events, anxiety, depression and coping mechanisms in patients with Behçet's disease. J Eur Acad Dermatol Venereol 2003; 17: 670–5
   PubMed Web of Science ®Google Scholar
• Epstein RS, Cumming NA, Sherwood EB, Bergsma DR. Psychiatric aspects of Behçet's syndrome. J Psychosom Res 1970; 14: 161–72
   PubMed Web of Science ®Google Scholar
• Uhl V, Reus VI, Fromm JB. Psychiatric symptoms in Behçet's syndrome. Psychosomatics 1985; 26: 547–9
   PubMed Web of Science ®Google Scholar
• Calikoğlu E, Önder M, Coşar B, Candansayar S. Depression, anxiety levels and general psychological profile in Behçet's disease. Dermatology 2001; 203: 238–40
   PubMed Web of Science ®Google Scholar
• Tanriverdi N, Taşkintuna İ, Dürü Ç, Özdal P, Ortaç S, Firat E. Health-releated quality of in Behçet patients with ocular involvement. Jpn J Ophthalmol 2003; 47: 85–92
   PubMed Web of Science ®Google Scholar
• International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078–80.
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Clinical Version (SCID–I/CV). American Psychiatric Press, Washington, DC 1997
   Google Scholar
• Çorapçioğlu A, Aydemir Ö, Yildiz M, Esen A, Köroğlu E. DSM–IV Eksen I Bozuklukları İçin Yapılandırılmiş Klinik Görüşme, Klinik Versiyon. Hekimler Yayın Birliği, Ankara 1999
   Google Scholar
• Sim M. Behçet's syndrome as a psychiatric disorder. Am J Psychiatry 1983; 140: 816
   PubMed Web of Science ®Google Scholar
• Borson S. Behçet's disease as psychiatric disorder: A case report. Am J Psychiatry 1982; 139: 1348–9
   PubMed Web of Science ®Google Scholar
• Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, et al. The prevalence of spesific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry 1987; 44: 727–35
   PubMed Web of Science ®Google Scholar
• Lee CK, Kwak YS, Yamamoto J, Rhee H, Kim YS, Han JH, et al. Psychiatric epidemiology in Korea. Part I: Gender and age differences in Seoul. J Nerv Ment Dis 1990; 178: 242–6
   PubMed Web of Science ®Google Scholar
• Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8–19
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Essau CA, von Zerssen D, Krieg JC, Zaudig M. Lifetime and six-month prevalence of mental disorders in the Munich follow-up study. Eur Arch Psychiatry Clin Neurosci 1992; 241: 247–58
   PubMed Web of Science ®Google Scholar
• Regier DA, Boyd JH, Burke JD, Rae DS, Myers JK, Kramer M, et al. One-month prevalence of mental disorders in the United States. Arch Gen Psychiatry 1988; 45: 977–86
   PubMed Web of Science ®Google Scholar
• Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic Catchment Area prospectives 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50: 85–94
   PubMed Web of Science ®Google Scholar
• Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD, et al. Lifetime prevalence of spesific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41: 949–58
   PubMed Web of Science ®Google Scholar
• Wilhelm K, Mitchell P, Slade T, Brownhill S, Andrews G. Prevalence and correlates of DSM-IV major depression in an Australian national survey. J Affect Disord 2003; 75: 155–62
   PubMed Web of Science ®Google Scholar
• Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a National Community Sample: The National Comorbidity Survey. Am J Psychiatry 1994; 151: 979–86
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 355–64
   PubMed Web of Science ®Google Scholar
• Faravelli C, Degl'Innocenti BG, Giardinelli L. Epidemiology of anxiety disorders in Florence. Acta Psychiatr Scand 1989; 79: 308–12
   PubMed Web of Science ®Google Scholar
• Ohayan MM, Priest RG, Guilleminault C, Caulet M. The prevalence of depressive disorders in the United Kingdom. Biol Psychiatry 1999; 45: 300–7
   PubMed Web of Science ®Google Scholar
• Akdeniz N, Eşrefoğlu M, Keleş MS, Karakuzu A, Atasoy M. Serum interleukin-2, interleukin-6, tumor necrosis factor-alpha and nitric oxide levels in patients with Behçet's disease. Ann Acad Med Singapore 2004; 33: 596–9
   PubMed Web of Science ®Google Scholar
• Öztaş MO, Önder M, Gürer MA, Bukan N, Sancak B. Serum interleukin 18 and tumor necrosis factor-alpha levels are increased in Behçet's disease. Clin Exp Dermatol 2005; 30: 61–3
   PubMed Web of Science ®Google Scholar
• Düzgün N, Ayaslioğlu E, Tutkak H, Aydintuğ OT. Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease. Rheumatol Int 2005; 25: 1–5
   PubMed Web of Science ®Google Scholar
• Marshall SE. Behçet's disease. Best Pract Res Clin Rheumatol 2004; 18: 291–311
   PubMed Web of Science ®Google Scholar
• Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H. Synergistic effects of interleukin-1β, interleukin-6, and tumor necrosis factor-α: central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 2000; 22: 566–80
   PubMed Web of Science ®Google Scholar
• Musselman DL, Miller AH, Porter MR, Manatunga AK, Gao F, Penna S, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001; 158: 1252–7
   PubMed Web of Science ®Google Scholar
• Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201–17
   PubMed Web of Science ®Google Scholar